Unknown

Dataset Information

0

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.


ABSTRACT: We critically evaluated the available evidence on genomic tests in breast cancer to define their prognostic ability and likelihood to determine treatment benefit.Independent evaluation of six genomic tests [Oncotype Dx™, MammaPrint(®), Genomic Grade Index, PAM50 (ROR-S), Breast Cancer Index, and EndoPredict] was carried out by a panel of experts in three parameters: analytical validity, clinical validity, and clinical utility based on the principles of the EGAPP criteria. PANEL STATEMENTS: The majority of the working group members found the available evidence on the analytical and clinical validity of Oncotype Dx™ and MammaPrint(®) to be convincing. None of the genomic tests demonstrated robust evidence of clinical utility: it was not clear from the current evidence that modifying treatment decisions based on the results of a given genomic test could result in improving clinical outcome.The IMPAKT 2012 Working Group proposed the following recommendations: (i) a need to develop models that integrate clinicopathologic factors along with genomic tests; (ii) demonstration of clinical utility should be made in the context of a prospective randomized trial; and (iii) the creation of registries for patients who are subjected to genomic testing in the daily practice.

SUBMITTER: Azim HA 

PROVIDER: S-EPMC6267878 | biostudies-other | 2013 Mar

REPOSITORIES: biostudies-other

altmetric image

Publications

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.

Azim H A HA   Michiels S S   Zagouri F F   Delaloge S S   Filipits M M   Namer M M   Neven P P   Symmans W F WF   Thompson A A   André F F   Loi S S   Swanton C C  

Annals of oncology : official journal of the European Society for Medical Oncology 20130120 3


<h4>Background</h4>We critically evaluated the available evidence on genomic tests in breast cancer to define their prognostic ability and likelihood to determine treatment benefit.<h4>Design</h4>Independent evaluation of six genomic tests [Oncotype Dx™, MammaPrint(®), Genomic Grade Index, PAM50 (ROR-S), Breast Cancer Index, and EndoPredict] was carried out by a panel of experts in three parameters: analytical validity, clinical validity, and clinical utility based on the principles of the EGAPP  ...[more]

Similar Datasets

| S-EPMC7027970 | biostudies-literature
| S-EPMC6394734 | biostudies-literature
| S-EPMC7339347 | biostudies-literature
| S-EPMC3705037 | biostudies-literature
| S-EPMC2655764 | biostudies-literature
| S-EPMC9746060 | biostudies-literature
| S-EPMC7033067 | biostudies-literature
| S-EPMC9681917 | biostudies-literature
| S-EPMC8633772 | biostudies-literature
| S-EPMC11343978 | biostudies-literature